Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Overview
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Companies Involved in Therapeutics Development
C4X Discovery Holdings PLC
Genentech Inc
Morphic Therapeutic Inc
Protagonist Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Drug Profiles
ET-3764 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
etrolizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PN-943 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Integrin Alpha4 and Beta7 for Inflammatory Bowel Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize ITGA4 and ITGB7 for Unspecified Indication - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Integrin Alpha4 and Beta7 for Inflammatory Bowel Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vedolizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Dormant Products
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Discontinued Products
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Product Development Milestones
Featured News & Press Releases
Mar 11, 2019: Takeda’s Entyvio achieves superior remission than Humira in ulcerative colitis
Mar 11, 2019: Takeda Cada announces positive results for ENTYVIO (vedolizumab) vs. Humira (adalimumab) in first IBD study to compare biological agents head-to-head
Dec 17, 2018: Entyvio post-marketing safety data consistent with previous clinical trials
Dec 13, 2018: Protagonist Therapeutics initiates phase 1 trial of oral, gut-restricted, alpha-4-beta-7 integrin antagonist PN-10943
Nov 27, 2018: Protagonist Therapeutics announces new development candidate PN-10943 for the treatment of inflammatory bowel disease
Nov 07, 2018: Takeda announces launch of Entyvio (vedolizumab) for the treatment of adult patients with moderately to severely active ulcerative colitis in Japan
Oct 27, 2018: Takeda comments on ongoing Phase 1 review by the European Commission of the proposed acquisition of Shire
Oct 22, 2018: Investigatiol subcutaneous formulation of Vedolizumab achieves and maintains clinical remission and mucosal healing at Week 52 in patients with moderately to severely active Ulcerative Colitis
Oct 08, 2018: New real-world data alyses support the long-term use of Entyvio (Vedolizumab) in bio-?ve patients for the treatment of moderate to severe ulcerative colitis or crohn’s disease
Jul 19, 2018: Takeda reports positive top-line outcomes from VISIBLE 1 trial
Jul 18, 2018: Takeda Submits an Application for a New Indication of Entyvio (vedolizumab) for the Treatment of Adult Patients with Moderately to Severely Active Crohn’s Disease in Japan
Jul 02, 2018: Takeda Obtains New Drug Application Approval for Entyvio (vedolizumab) for the Treatment of Ulcerative Colitis in Japan
Jun 05, 2018: Alysis of real-world safety data shows gut-selective ENTYVIO (vedolizumab) had fewer serious infections and adverse events than those on systemic TNFa-antagonist therapy in ulcerative colitis and Crohn’s disease patients
Jun 03, 2018: Takeda Highlights Favorable Safety Profile of Entyvio (vedolizumab) Through Comparative Real-World Data Versus TNFa-Antagonist Therapy in Ulcerative Colitis and Crohn’s Disease
May 15, 2018: Bio-Rad Introduces Anti-Vedolizumab Antibodies
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Top 10 Indications, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019


List of Tables


Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Indication, H1 2019
Number of Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Pipeline by C4X Discovery Holdings PLC, H1 2019
Pipeline by Genentech Inc, H1 2019
Pipeline by Morphic Therapeutic Inc, H1 2019
Pipeline by Protagonist Therapeutics Inc, H1 2019
Pipeline by Takeda Pharmaceutical Co Ltd, H1 2019
Dormant Projects, H1 2019
Discontinued Products, H1 2019